In a recent study posted to the bioRxiv* preprint server, researchers used a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein-pseudotyped viral model to characterize SARS ...
Human neutralizing antibodies against SARS-CoV-2 are isolated from the convalescent patient. A high affinity monoclonal antibody mAb-39 neutralizes SARS-CoV-2 original strain and Omicron variants, as ...
How could we forget the SARS-CoV-2 pandemic, right? It’s now part of our history, a story to pass on to the next generation. There are hundreds of related SARS-CoV strains known to infect different ...
As we approach the five-year anniversary of the COVID-19 pandemic, it is worth reflecting not only on the paradigm-shifting impact of the initial outbreak, but also on how SARS-CoV-2 continues to ...
The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people ...
An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...
Gene‑edited HPSCs programmed to make therapeutic antibodies and proteins show long‑lasting, boostable immunity in mouse models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results